Related Experiment Video
Updated: Dec 13, 2025

Renal Ischaemia Reperfusion Injury: A Mouse Model of Injury and Regeneration
Published on: June 7, 2014
Methylation in pericytes after acute injury promotes chronic kidney disease
Yu-Hsiang Chou1,2,3, Szu-Yu Pan1,3,4, Yu-Han Shao3
1Renal Division, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Abstract:
The origin and fate of renal myofibroblasts is not clear after acute kidney injury (AKI). Here, we demonstrate that myofibroblasts were activated from quiescent pericytes (qPericytes) and the cell numbers increased after ischemia/reperfusion injury-induced AKI (IRI-AKI). Myofibroblasts underwent apoptosis during renal recovery but one-fifth of them survived in the recovered kidneys on day 28 after IRI-AKI and their cell numbers increased again after day 56. Microarray data showed the distinctive gene expression patterns of qPericytes, activated pericytes (aPericytes, myofibroblasts), and inactivated pericytes (iPericytes) isolated from kidneys before, on day 7, and on day 28 after IRI-AKI. Hypermethylation of the Acta2 repressor Ybx2 during IRI-AKI resulted in epigenetic modification of iPericytes to promote the transition to chronic kidney disease (CKD) and aggravated fibrogenesis induced by a second AKI induced by adenine. Mechanistically, transforming growth factor-β1 decreased the binding of YBX2 to the promoter of Acta2 and induced Ybx2 hypermethylation, thereby increasing α-smooth muscle actin expression in aPericytes. Demethylation by 5-azacytidine recovered the microvascular stabilizing function of aPericytes, reversed the profibrotic property of iPericytes, prevented AKI-CKD transition, and attenuated fibrogenesis induced by a second adenine-AKI. In conclusion, intervention to erase hypermethylation of pericytes after AKI provides a strategy to stop the transition to CKD.
Insights
Renal myofibroblasts originate from pericytes after acute kidney injury (AKI). Epigenetic changes in these cells promote chronic kidney disease (CKD) progression, but demethylation therapy can prevent this transition.
Area of Science:
- Nephrology
- Cell Biology
- Epigenetics
Background:
- The origin and long-term fate of renal myofibroblasts following acute kidney injury (AKI) remain unclear.
- Pericytes are implicated in kidney repair, but their transformation into myofibroblasts and subsequent role in disease progression require further elucidation.
Purpose of the Study:
- To investigate the origin and fate of renal myofibroblasts after ischemia/reperfusion injury-induced AKI (IRI-AKI).
- To explore the epigenetic mechanisms regulating pericyte function and their role in the transition from AKI to chronic kidney disease (CKD).
- To evaluate the therapeutic potential of demethylation in preventing AKI-CKD transition and mitigating renal fibrosis.
Main Methods:
- Isolation and gene expression profiling (microarray) of quiescent (qPericytes), activated (aPericytes/myofibroblasts), and inactivated (iPericytes) from kidneys at different time points post-IRI-AKI.
- Analysis of Acta2 gene regulation, including Ybx2 methylation and transforming growth factor-β1 (TGF-β1) signaling.
- In vivo administration of 5-azacytidine (a demethylating agent) to assess its effects on renal recovery, fibrosis, and AKI-CKD transition following IRI-AKI and a second AKI.
Main Results:
- Myofibroblasts are activated from qPericytes post-IRI-AKI, with a subset surviving and proliferating long-term.
- Hypermethylation of the Acta2 repressor Ybx2 in iPericytes promotes AKI-CKD transition and exacerbates fibrogenesis.
- TGF-β1 induces Ybx2 hypermethylation, increasing α-smooth muscle actin expression in aPericytes.
- 5-azacytidine treatment restored microvascular function, reversed profibrotic properties, prevented AKI-CKD transition, and attenuated fibrosis after a second AKI.
Conclusions:
- Pericyte epigenetic dysregulation, specifically Ybx2 hypermethylation, is a key driver of AKI-CKD transition.
- Intervention targeting pericyte hypermethylation offers a promising strategy to halt AKI-CKD progression.
- Demethylation therapy presents a potential therapeutic approach to improve long-term kidney outcomes after AKI.
More Related Videos
Related Concept Videos
Acute Kidney Injury II: Pathophysiology
Chronic Kidney Disease I: Introduction
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention

